Takeda Pharmaceutical Company Limited

Takeda betont bei internationaler wissenschaftlicher Sitzung die Fortschritte zu lysosomalen Speichererkrankungen

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK (https://c212.net/c/link/?t=0&l=de&o=23646 89-1&h=1585860007&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l% 3Den%26o%3D2364689-1%26h%3D1920452667%26u%3Dhttps%253A%252F%252Fwww.t akeda.com%252Finvestors%252F%26a%3DTSE%253A ...

04.02.2019 | Gesundheitswesen - Medizin